DOR to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation

Enrique Grande shared a post on X:

”Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy with TP53 Mutation.

Authors: Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R. Wilson, Sagar A. Naik, Vivek Subbiah, Matthew T. Campbell, Pavlos Msaouel, Parminder Singh, Omar Alhalabi.”

Source: Enrique Grande/X

Enrique Grande, MD, PhD, MSc, is the Director of the Medical Oncology Program and Clinical Research lead at MD Anderson Cancer Center Madrid. Dr. Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit. He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE). Dr. Grande edits several international journals and has participated in recent neuroendocrine tumor trials that led to the approval of new drugs in this field.